000504，终止筹划重大资产重组

Core Viewpoint - The company *ST Bio has announced the termination of its major asset restructuring plan, which was initially aimed at acquiring a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. The decision was made after negotiations failed to reach a consensus among the parties involved [1][3][4]. Summary by Sections Termination of Restructuring - The company disclosed that it had been actively pursuing the major asset restructuring in accordance with relevant laws and regulations since the announcement on August 12, 2025. However, after multiple rounds of discussions, the parties could not reach an agreement, leading to the mutual decision to terminate the transaction [3][4]. Impact on Operations - The termination of the transaction is stated to have no significant adverse impact on the company's current operations or financial status. The company maintains that its operational order is normal and that the termination does not harm the interests of shareholders, particularly minority shareholders [4]. Financial Performance - On the same day, the company released its earnings forecast for 2025, projecting a net profit attributable to shareholders of between 28.5 million and 32.5 million yuan, marking a turnaround from a loss in the previous year [4]. - The company reported a total profit of 18.5 million to 26.5 million yuan, compared to a loss of 20.85 million yuan in the same period last year. The revenue is expected to be between 385 million and 425 million yuan, significantly up from 134.45 million yuan in the previous year [5]. - The increase in revenue is attributed to the acquisition of a controlling stake in Loudi Jinhong New Materials Co., Ltd., which enhanced the company's recycling business, as well as the expansion of sales in related products such as beauty and health products [5].